ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 6, 2018
Dividend Growth Portfolio: Adding Two New Gems
We’re making some moves in the Dividend Growth Newsletter portfolio today.
Apr 5, 2018
Walgreens Boots Alliance Remains at the Crossroads of a Rapidly-Evolving Healthcare Landscape
Image Source: Walgreens 2Q 2018 Earnings Release. The evolving healthcare landscape has been dealing with the threat of a disruptive new competitor entering the market and considerable political risk. Though the need for healthcare remains impervious to economic forces, a clear deflationary trend has descended on the industry that has affected many of the well-entrenched participants. Let’s examine Walgreens Boots Alliance for clues that a shift in sentiment may have occurred in this well known, yet beleaguered sector.
Apr 4, 2018
Valuentum Website Navigation
Just a couple quick notes.
Apr 3, 2018
Alert: Dropping P&G; Also -- Intel's Dividend Hike; General Motors Puts Up Strong March Sales
We were reminded of some good news from Intel and General Motors today, but the time has come to part with Procter & Gamble. We may have included it in the simulated Dividend Growth Newsletter portfolio too long.
Apr 2, 2018
Trump Knocks Air Out of Amazon; Intel Investors Overreact to Apple News
Only fools, or worse, are saying that our money losing Post Office makes money with Amazon. THEY LOSE A FORTUNE, and this will be changed. Also, our fully tax paying retailers are closing stores all over the country...not a level playing field! — Donald J. Trump (@realDonaldTrump) April 2, 2018 President Trump continues to move markets, and his messages about Amazon haven’t gone unnoticed. Apple seems to be targeting wider gross margins in coming years, as it looks to bring in-house a part of its supply chain. Intel’s shares overreact.
Apr 2, 2018
Why Some Investors Fail -- Worms!
Image Source: crabchick. When you read our research, we’re not just providing financial metrics -- Valuentum is striving to provide an answer to the most important question in investing: what is a company worth? Though there are varying opinions about which underlying factor is the most important investment consideration, at the end of the day, the process of valuation collects every investment consideration to provide a conclusion. It is the answer after all other considerations, the final outcome of analysis. It is why we say that investors that don't pay attention to valuation may be doomed to fail...eventually. Not seeking valuation is not seeking the answer.
Mar 29, 2018
Verint’s Big Move Puts It Ahead of the Market
We think Verint Systems is getting a bad rap about its non-GAAP reporting. Operating cash flow at the company is tremendous, and the market may finally be coming around to recognizing its undervalued nature.
Mar 29, 2018
Dividend Highlights in Big Pharma
The first quarter of 2018 will go down in the record books as one of the most volatile in recent memory--a sharp jump out of the gate was met with significant selling at the end of March as numerous political and economic worries entered the picture. We believe a timely review of some of the dividend stalwarts is in order.
Mar 28, 2018
PCSK9 Woes Weigh on Amgen and Regeneron
Image shown: Amgen and Regeneron have both meaningfully trailed the market since October of 2017. The robustness of the clinical pipeline offers an important clue regarding the health and vitality of a biotech/pharma company, as the clinical pipeline is critical towards maintaining and growing the top line. One of the most promising, and dare-we-say, overhyped new treatments to enter the market is the PCSK9 cholesterol-lowering agents, with Amgen and Regeneron leading the pack. Let’s discuss the results of Regeneron’s treatment along with a discussion of the path forward for the treatment.
Mar 27, 2018
Tesla’s Shares Get Hammered
Tesla’s shares have been overpriced for some time, but the Valuentum Buying Index system didn’t raise a big red flag until mid-June of last year. Shares have been getting hammered.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.